Trending...
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
America's first at-home reflux test can be ordered online at www.pepsincheck.com
HOUSTON - PennZone -- UK healthcare innovator, RD Biomed, developed Peptest, the world's first non-invasive test for reflux, in 2007. Since that time it has grown to global prominence. Shipping costs and wait times were a barrier to the U.S. market preventing the adoption of this direct to consumer diagnostic test. Now with Restech managing the PepsinCheck operations, the test is shipped from the U.S., processed at strategically located American labs, and results are sent back to the consumer by mail and a secure email within about a week.
Both PepsinCheck (U.S. market) and Peptest (non-U.S. markets) are manufactured by RD Biomed to the same global standard. The test detects the presence of the stomach enzyme pepsin (recognized as a reliable diagnostic biomarker for reflux) in saliva and sputum samples.
Restech VP of Clinical Affairs, Thomas Ball, commented, "As we Rethink Reflux across the continuum of care, direct to consumer healthcare plays a pivotal role. RD Biomed and the Peptest provide an ideal accompaniment to our product portfolio, ensuring that tough diagnostic cases find appropriate physician-based care in addition to broadening our reach to an unprecedented range of patients. PepsinCheck represents the first at-home reflux testing in the US market and holds the potential to revolutionize the care of individuals with symptoms ranging from heartburn, to chronic cough, and even obstructive sleep apnea."
More on The PennZone
Professor Peter Dettmar, Director of RD Biomed, said: "We're thrilled that our salivary pepsin test for diagnosing reflux has officially launched in the US. It has been a pleasure working with Restech, a successful digestive health solutions company, and we could not have chosen a better company to distribute and commercialise PepsinCheck by Peptest."
About Restech
At Restech, we believe there is a better way to manage reflux. Our team designed and launched the first real-time sensor that could function highly accurately in a non-liquid environment. Since then, we've obsessed over reflux, developing and seeking out new products across the diagnostic and therapeutic continuum. www.restech.com
About RD Biomed & Peptest
RD Biomed is a pharmaceutical development and diagnostic company based at Castle Hill Hospital in Hull, East Yorkshire. Innovators in healthcare product development, RD Biomed focusses on gastroenterology and wound management and develops products that identify, prevent and treat various medical conditions. www.peptest.co.uk
More on The PennZone
CONTACTS
Thomas Ball
Vice President of Clinical Affairs
T: 1.800.352.1512
E: tball@restech.com
Harvey Dettmar
Director, RD Biomed Limited
T: +44 1482 461866
E: harvey.dettmar@technostics.com
www.pepsincheck.com
Both PepsinCheck (U.S. market) and Peptest (non-U.S. markets) are manufactured by RD Biomed to the same global standard. The test detects the presence of the stomach enzyme pepsin (recognized as a reliable diagnostic biomarker for reflux) in saliva and sputum samples.
Restech VP of Clinical Affairs, Thomas Ball, commented, "As we Rethink Reflux across the continuum of care, direct to consumer healthcare plays a pivotal role. RD Biomed and the Peptest provide an ideal accompaniment to our product portfolio, ensuring that tough diagnostic cases find appropriate physician-based care in addition to broadening our reach to an unprecedented range of patients. PepsinCheck represents the first at-home reflux testing in the US market and holds the potential to revolutionize the care of individuals with symptoms ranging from heartburn, to chronic cough, and even obstructive sleep apnea."
More on The PennZone
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025
- Colbert Packaging Announces WBENC Recognition
- SHI Cryogenics Group Launches Highest-Capacity Single-Stage Cryocoolers to Date
Professor Peter Dettmar, Director of RD Biomed, said: "We're thrilled that our salivary pepsin test for diagnosing reflux has officially launched in the US. It has been a pleasure working with Restech, a successful digestive health solutions company, and we could not have chosen a better company to distribute and commercialise PepsinCheck by Peptest."
About Restech
At Restech, we believe there is a better way to manage reflux. Our team designed and launched the first real-time sensor that could function highly accurately in a non-liquid environment. Since then, we've obsessed over reflux, developing and seeking out new products across the diagnostic and therapeutic continuum. www.restech.com
About RD Biomed & Peptest
RD Biomed is a pharmaceutical development and diagnostic company based at Castle Hill Hospital in Hull, East Yorkshire. Innovators in healthcare product development, RD Biomed focusses on gastroenterology and wound management and develops products that identify, prevent and treat various medical conditions. www.peptest.co.uk
More on The PennZone
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Federated Hermes Premier Municipal Income Fund declares dividend
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
CONTACTS
Thomas Ball
Vice President of Clinical Affairs
T: 1.800.352.1512
E: tball@restech.com
Harvey Dettmar
Director, RD Biomed Limited
T: +44 1482 461866
E: harvey.dettmar@technostics.com
www.pepsincheck.com
Source: Respiratory Technology Corporation
Filed Under: Health
0 Comments
Latest on The PennZone
- The Waite Launches: A Curated Motherhood Marketplace For Every Stage
- Affordable, High-Quality Care: Cheap Braces for Adults Available from Exeter Smiles in Reading
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- Sci-Fi Novel from Pittsburgh Author Explores Love, Power, & Humanity in an Age of Artificial People
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
- Greenlight Networks to Acquire Loop Internet
- Finding the Best AC Repair Service in Philadelphia
- Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
- Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
- Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
- Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
- Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
- Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
- Phillie Phanatic Joins the Together We Dance Foundation's Summer Dance Team to Celebrate Inclusion
- Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
- Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
- CLASS ACTION NOTICE: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Class Action
- e4health Earns 2025-2026 Great Place To Work Certification™ for Fourth Consecutive Year
- Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest